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Abstract  
Leucine-rich repeat kinase 2 (LRRK2) is a central protein in the pathogenesis of 
Parkinson’s disease (PD), yet its normal function has proven stubbornly hard to 
elucidate. Even though it remains unclear how pathogenic mutations affect LRRK2 to 
cause PD, recent findings provide increasing cause for optimism. We summarise here 
the developing consensus over the effect of pathogenic mutations in the Roc and COR 
domains on LRRK2 GTPase activity. This body of work has been greatly reinforced by 
our own study of the protective R1398H variant contained within the LRRK2 GTPase 
domain. Collectively, data point toward the pathogenicity of GTP-bound LRRK2, and 
strengthen a working model for LRRK2 GTPase function as a GTPase-activated by 
dimerisation. Together with the identification of the protective R1398H variant as a 
valuable control for pathogenic mutations, we have no doubt that these triumphs for 
the LRRK2 field will accelerate research towards resolving LRRK2 function, and 
towards new treatments for PD.  
Introduction 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder 
worldwide and is characterised by resting tremor, akinesia, bradykinesia and 
postural instability, although additional non-motor symptoms are common. 
Parkinsonian symptoms coincide with the death of dopaminergic neurons in the 
substantia nigra pars compacta, with degeneration eventually spreading to other 
brain regions [1].   
 
Mutations have been identified in several genes causing familial PD [2]. Of particular 
interest is LRRK2, which encodes Leucine-rich repeat kinase 2 (LRRK2). LRRK2 
mutations account for 1-40% of PD cases in different populations, and present 
symptoms and brain pathologies that closely resemble idiopathic PD [2,3]. However, 
the precise function of LRRK2 remains a mystery.  
 
LRRK2 consists of a catalytic core incorporating Ras of complex proteins (Roc), C-
terminal of Roc (COR), and kinase domains, which is flanked by several protein-
protein interaction domains (Figure 1) [4]. Seven LRRK2 missense mutations 
segregate with PD, namely N1437H, and R1441C/G/H in the Roc domain, Y1699C in 
the COR domain, and G2019S and I2020T in the kinase domain [4]. Additional 
variants that increase PD susceptibility have been identified in the COR (R1628P) and 
WD40 (G2385R) domains [5,6].  
 
Here we review data relating to the effect of hereditary mutations on LRRK2 GTPase 
function. We argue that there is an overwhelming consensus about the effect of PD-
causing mutations on GTPase activity that is strengthened by our own study of the 
R1398H protective variant. Thus in contrast to the view that the LRRK2 field is largely 
in disagreement, the relationship between GTPase activity and disease susceptibility 
may be resolved.   
LRRK2 GTPase Domain: GAD or small GTPase?  
The clustering of pathogenic mutations within the Roc domain, has established this 
domain as central to LRRK2 pathology. The Roc domain is a bona-fide GTPase [7-10], 
and is important for the rest of the molecule, since LRRK2 kinase activity is dependent 
on the binding of guanine nucleotides [11]. Nonetheless, the precise mechanism 
underpinning GTPase activity is the subject of debate, with two competing models in 
existence. These are summarised below. 
 
The Ras Small GTPase Model. Based on homology to Ras-like GTPases, the LRRK2 Roc 
domain has been suggested to function analogously to small GTPases. Small GTPases 
act as molecular switches, with binding to effector proteins dictated by whether they 
are in the ‘inactive’ (GDP-bound) or ‘active’ (GTP-bound) states. For Ras itself, the 
best-described effectors are Raf kinases. These preferentially bind GTP-bound Ras, 
triggering Raf activation, with the hydrolysis of GTP to GDP terminating the signal 
[12]. 
 
Small GTPases are switched between active and inactive states by protein-protein 
interactions with guanine nucleotide exchange factors (GEFs) and GTPase activating 
proteins (GAPs). GEFs overcome the slow dissociation of GDP while GAPs enhance 
GTP hydrolysis (Figure 2) [13,14]. Thus, GAPs promote the GDP-bound state and are 
considered inhibitory, whereas GEFs promote the GTP-bound state and are 
considered activators. However, since GAPs and GEFs are both required for small 
GTPase function, these proteins have the effect of increasing GTPase activity in vitro.  
 
Supporting this model, several publications report candidate LRRK2 GAPs and GEFs. 
These include ArfGAP1, which binds LRRK2 in mammalian cells and increases GTP 
hydrolysis in vitro [15,16], and RGS2, which is also reported to increase GTP 
hydrolysis [17]. The only suggested LRRK2 GEF is ARHGEF7, which enhances GTP 
hydrolysis and promotes GTP exchange in vitro [18,19]. These observations come 
with the caveat that LRRK2 interacts with a number of small GTPases that could be 
targets of ArfGAP1, RGS2 and/or ARHGEF7 and may be present in the assays as 
contaminants [20]. More concerningly, none of these proteins bind directly to the Roc 
domain. Taking these observations together, ArfGAP1, RGS2 and ARHGEF7 may 
modulate LRRK2 GTPase activity, but their mechanism of action is distinct from the 
GEFs and GAPs of small GTPases.  
 
The GTPase Activated by Dimerisation (GAD) Model. Advocates of the GTPase activated 
by dimerisation (GAD) model propose a mechanism for LRRK2 GTPase function that 
is based around homology with prokaryotic Roco proteins. This model differs from 
the small GTPase model in three key aspects (Figure 2). Firstly, the GAD model 
requires the LRRK2 Roc and COR domains to act as a single functional unit: a so-called 
RocCOR tandem domain. This idea is quite persuasive since these domains are found 
together throughout nature [21]. Secondly, the GAD model requires LRRK2 to 
function as a homodimer, with dimerisation mediated by the COR domain [22]. And 
thirdly, the GAD model does not require GAPs or GEFs.  
 
Some interesting observations support this model. Most notably, a number of reports 
indicate that LRRK2 is largely dimeric in vivo, and dimerisation appears crucial for 
kinase activity [23-25]. In addition, the prokaryotic Roco structure predicts that the 
intramolecular Roc-COR interface is particularly important. Residues at this location 
are highly conserved across evolution, while a number of pathogenic LRRK2 
mutations are predicted to reside at this interface. Consistently, these mutations have 
the same effects on GTPase activity in prokaryotic Roco proteins and human LRRK2 
[22,26].  
All PD-causing RocCOR mutations increase the proportion of GTP-
bound LRRK2, whilst the protective R1398H mutation has the 
opposite effect 
A number of genetic linkage studies have identified an R1398H LRRK2 Roc domain 
mutant as a protective variant [27-29]. R1398H is the only variant of this type 
identified to date but has the potential to revolutionise the study of LRRK2 biology, 
since it can be expected to have the opposite effect to PD-causing mutations in 
disease-relevant processes.  
 
We have recently reported the effects of R1398H on LRRK2 GTPase function, and 
found data consistent with its status as a protective variant [30]. In particular, 
R1398H displayed decreased binding to GTP and increased GTP hydrolysis. Thus, 
R1398H appears to shift LRRK2 towards the GDP-bound state. Remarkably, this is the 
opposite to all reports for pathogenic RocCOR tandem domain mutations (Table 1). 
Taken together, these observations are consistent with GTP-bound LRRK2 being 
pathogenic, and raise the possibility of targeting LRRK2 GTP-binding for PD 
treatment. Intriguingly, a LRRK2 GTP-binding inhibitor has been reported to reduce 
neurodegeneration in mouse models [31]. How such compounds transfer to human 
PD patients remains to be seen, but their potential is promising. 
 
We also found R1398H to increase interaction between RocCOR tandem domain 
constructs in yeast two-hybrid assays [30]. This is in contrast to the pathogenic 
R1441C/G/H and Y1699C mutations, which weaken interaction. We do not know 
which of the many potential inter or intramolecular interactions within a RocCOR 
dimer are affected, although it is unlikely to be COR-COR dimerisation, since the data 
are largely recapitulated in assays that use the RocCOR tandem domain as bait, but 
use an isolated Roc domain as prey [30]. In any case, the changes in interaction 
strength seen in this assay correlate with altered GTPase function: R1398H increases 
LRRK2 dimerisation and decreases GTP binding; pathogenic mutants have the 
opposite effect.  
 
These observations are consistent with LRRK2 functioning as a dimeric GTPase that 
involves both Roc and COR domains, rather than as a monomeric Roc domain. 
Strikingly, molecular modelling of pathogenic and protective RocCOR mutations 
using the prokaryotic Roco structure makes this case even stronger, since the 
equivalent residues to R1398, N1347, R1441 and Y1699 are in remarkably close 
spatial proximity at the intramolecular Roc-COR interface [22,30]. In the case of 
R1398, mutation to histidine may prevent the formation of a Roc-COR hydrogen bond 
[30]. Based on this structural information, we and others have speculated that 
pathogenic and protective variants within the LRRK2 RocCOR domain all affect 
GTPase function by altering intramolecular Roc-COR interactions [22,30,32]. 
Interestingly, this has been demonstrated for the Y1699C mutation which is located 
within the COR domain but still affects GTPase activity, further supporting the GAD 
model [32]. Indeed, mutations at residues equivalent to R1441 and Y1699 in 
prokaryotic Roco proteins recapitulate the impaired GTP hydrolysis seen in human 
LRRK2 [7,22,32]. 
 
The GAD model also has serendipitous support from other studies of the R1398 site. 
Based on homology to Ras proteins, an artificial R1398L mutation was generated to 
mimic the tumorigenic Q61L substitution that renders Ras proteins constitutively 
GTP-bound. Contrary to expectation however, R1398L behaved like R1398H by 
decreasing GTP-binding and increasing GTP hydrolysis (Table 1) [15,30,33,34]. It is 
self-evident that behaviour opposite to that predicted from Ras is a strong argument 
against the small GTPase model, but the fact that R1398L would also prevent the same 
putative Roc-COR hydrogen bond as R1398H makes a tantalizing case for the GAD 
model. 
Pathomechanisms for mutations outside the RocCOR tandem 
domain 
The above data make a compelling argument for PD-causing RocCOR mutants shifting 
LRRK2 to the GTP-bound state. But what about mutations outside the RocCOR 
tandem domain? It has long been suggested that LRRK2 kinase activity may govern 
GTPase function through autophosphorylation mechanisms, and in agreement with 
this, Roc domain autophosphorylation is reported to modulate GTPase function 
[35,36]. Based on this, one would expect mutations that alter kinase activity to 
indirectly affect GTPase function. However, the G2019S kinase domain mutation, 
which increases LRRK2 kinase activity, has been demonstrated repeatedly to have no 
affect on GTP-binding or GTP hydrolysis [10,15,33,34,37-39]. At the other extreme of 
kinase activity, an artificial kinase-dead mutation also has no effect [34]. It is perhaps 
surprising that the effects of altered kinase activity and autophosphorylation should 
be in conflict, but we note that autophosphorylation levels for LRRK2, even G2019S, 
are very low [35,40]. Thus, whilst the behaviour of hyper- and hypo-phosphorylated 
LRRK2 may be different in in vitro GTP-binding and hydrolysis assays, the range of 
Roc domain autophosphorylation achievable in cells may be insufficient to affect 
GTPase function. As such we would argue that “kinase activity controls GTPase 
activity” models appear unlikely (for this reason the possibility that the two 
enzymatic activities are connected is not included in Figure 3). The only other 
publication describing non-RocCOR mutations in GTPase assays is a surprising recent 
report of increased GTPase activity with the pathogenic I2020T kinase domain and 
G2385R WD40 domain mutations [41]. These observations cannot be ignored, but 
since they are contrary to every single publication for pathogenic RocCOR mutations, 
these experiments need replicating. In any case, it is clear that alternative 
pathomechanisms to increased GTP-binding must exist. So what could they be (Figure 
3)? 
 
The most obvious pathomechanism for non-RocCOR mutations is increased substrate 
phosphorylation. Substrate phosphorylation is a distinct concept to kinase activity, 
since the phosphorylation of substrate protein is dependent on more than just kinase 
activity. This is an important distinction, since G2019S remains the only mutation for 
which elevated kinase activity is agreed; even the adjacent I2020T mutation seems 
unable to elicit a reproducible effect [9,42-44] Perhaps more tellingly, the WD40 
domain G2385R risk variant impairs kinase activity [44,45]. It would be surprising if 
both increased and decreased LRRK2 kinase activity were able to cause PD, but 
G2019S and G2385R could still have the same effect on substrate phosphorylation, 
for example by differentially affecting kinase-substrate binding. With this in mind, we 
note a recent report of a group of Rab GTPases (Rabs 8/10/12) as LRRK2 kinase 
substrates [46]. Remarkably, all pathogenic LRRK2 mutations examined increased 
Rab phosphorylation in cells. These included mutations that do not affect kinase 
activity, as well as the kinase-enhancing G2019S and kinase-impairing G2385R 
mutations [46].  It is worth contrasting this with LRRK2 autophosphorylation at 
serine-1292, which is also increased by multiple PD-causing mutations [47,48]. In 
both cases, mutations outside the kinase domain enhance substrate phosphorylation 
at least as well as G2019S [46-48], thereby demonstrating a lack of correlation 
between kinase activity and substrate phosphorylation, and illustrating the need to 
dissociate these concepts. Presumably non-kinase domain mutations increase serine-
1292 autophosphorylation by making this residue more accessible to the kinase 
domain. Of the two, we would argue that Rab8/10/12 phosphorylation is more likely 
to have pathological relevance, since the stoichiometry of in vitro Rab8/10/12 
phosphorylation compares favourably to LRRK2 autophosphorylation [46]. Perhaps 
more importantly, serine-1292 autophosphorylation appears to be unaffected by 
G2385R [47]. But in any case, both are exciting stories and we await the next 
developments: it will be intriguing to examine how R1398H affects these 
phosphorylation events.  
 
Besides its enzymatic activities, LRRK2 has a remarkable number of reported 
interactors (currently 151 on BIOGRID, 
http://thebiogrid.org/125700/summary/homo-sapiens/lrrk2.html) and likely 
functions as a scaffold protein, nucleating multi-protein complexes through protein-
protein interactions [49,50].  It is self-evident that mutations in protein-protein 
interaction domains could alter binding to LRRK2, while RocCOR mutations have also 
been shown to affect binding to certain interactors [51-54]. How mutations in the 
kinase domain might do the same is less intuitive, although altered ATP binding and 
autophosphorylation are likely to affect the topology of LRRK2. In any case, there are 
numerous reports of altered protein binding to pathogenic LRRK2 mutants, including 
deregulated interactions with the G2019S and I2020T kinase domain mutants (e.g. 
FADD, GSK3β, Rac1 [52,55,56]). It is easy to envision how changes to any one of the 
individual protein-protein interactions within a multi-protein complex could elicit 
the same functional outcome. Thus, altered protein-protein interaction is a 
persuasive explanation for both RocCOR and non-RocCOR mutations. 
Concluding remarks 
Data from the study of pathogenic RocCOR mutations and the R1398H protective 
variant allow two conclusions to be drawn. Firstly, increased GTP-binding is a 
common pathomechanism for RocCOR mutations; and secondly, the GAD GTPase 
model for LRRK2 appears likely. It therefore seems reasonable to infer that GTP-
bound LRRK2 is a pathogenic species, and the GDP-bound form protective. This raises 
the possibility of treating LRRK2 PD – and perhaps idiopathic PD – with compounds 
that disrupt GTP binding. As mentioned, this therapeutic strategy is already under 
development, with encouraging results [31]. 
 
It should be reiterated that pathogenic mutations outside the RocCOR domain do not 
all affect LRRK2 GTPase function. Nonetheless, it is logical to assume that the effects 
of all pathogenic LRRK2 mutations converge at some point downstream. This point 
of convergence is perhaps the Holy Grail of LRRK2 biology. Currently, LRRK2 has been 
linked to a multitude of cellular processes, but those with pathological relevance are 
not agreed. However, we believe the R1398H mutant has the potential to greatly 
expedite LRRK2 research, since this mutant represents a powerful control that gives 
greater confidence to experiments producing small changes. When studied in cellular 
assays relevant to LRRK2 PD, R1398H can be expected to behave oppositely to PD-
causing mutants. With this in mind we note that R1398H increases canonical Wnt 
signalling activity [30], which is in direct contrast to pathogenic variants throughout 
LRRK2 [30,53]. Given the established importance of properly regulated Wnt 
signalling for the normal function of neurons, these observations could have great 
implications. Of course, R1398H has yet to be studied in many of the other processes 
in which LRRK2 has been implicated, and may present opposite effects in some of 
these assays too. 
 
A cure for LRRK2 Parkinson’s disease remains a long way off, but advances are being 
made. In particular the data supporting a model for LRRK2 GTPase function as 
described herein appear overwhelming. As such, determining the role of LRRK2 
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I1371V Full Length (M) ↑ (Pd) ns ↑ GTP-bound [11] 
“I1371”V 
C.tepidum Roc + 
COR (B) 
— (F)* ↓↓↓ (Pu) ↑ GTP-bound [22] 
“I1371”A 
C.tepidum Roc + 
COR(B) 
— (F)* ↓↓↓ (Pu) ↑ GTP-bound [22] 
N1437H Full Length (M) ↑↑↑ (Pd) ns ↑ GTP-bound [39] 
R1441C Full Length (M) ↑ (Pd) ns ↑ GTP-bound [11] 
R1441C Roc (M) — (R) ↓↓ (Pu) ↑ GTP-bound [9] 
R1441C Full Length (M) — (Pd) ↓ (Pu) ↑ GTP-bound [8] 
R1441C Roc (B) ns ↓ (Pu) ↑ GTP-bound [57] 
R1441C Full Length (M) ↑↑↑ (M) ns ↑ GTP-bound [39] 
R1441C Full Length (M) ns ↓ (IP) ↑ GTP-bound [33] 
R1441C 
Roc + COR +kinase 
(Y) 
— (Pd) — (IP)** No change [33] 
R1441C 
LRR + Roc + COR 
+kinase + WD40 (I) 
ns ↓ (Pu) ↑ GTP-bound [36] 
R1441C Full Length (M) ↑↑ (Pd) ns ↑ GTP-bound [16] 
R1441G Full Length (M) ↑ (Pd) ns ↑ GTP-bound [11] 
R1441G Roc (M) — (R) ↓↓ (Pu) ↑ GTP-bound [9] 
R1441G Full Length (M) ns ↓ (IP) ↑ GTP-bound [33] 
R1441H Roc (B) ↑ (F) ↓↓ (Pu) ↑ GTP-bound [58] 
"R1441"A 
C.tepidum Roc + 
COR (B) 
— (F)* ↓↓↓ (Pu) ↑ GTP-bound [22] 
Y1699C Full Length (M) ↑ (Pd) ns ↑ GTP-bound [11] 
Y1699C Full Length (M) ns ↓ (IP) ↑ GTP-bound [33] 
Y1699C Full Length (M) — (Pd) ↓↓ (Pu) ↑ GTP-bound [32] 
Y1699C Full Length (M) ↑↑ (Pd) ns ↑ GTP-bound [16] 
"Y1699"C 
C.tepidum Roc + 
COR (B) 
— (F)* ↓↓↓ (Pu) ↑ GTP-bound [22] 
R1398H Full Length (M) ↓↓ (Pd) ↑ (Pu) ↓ GTP-bound [30] 
T1343G Full Length (M) — (Pd) — (IP) — [34] 
D1994A Full Length (M) — (Pd) — (IP) — [34] 
R1398L 
Roc + COR + kinase 
(Y) 
↓ (Pd) ↑ (IP) ↓ GTP-bound [33] 
R1398L Full Length (M) ns ↑↑ (IP) ↓ GTP-bound [16] 
R1398L Full Length (M) — (Pd) ↑↑ (IP) ↓ GTP-bound [34] 
R1398L/T1343V Full Length (M) — (Pd) ↓↓ (IP) ↑ GTP-bound [34] 
R1398L/G2019S Full Length (M) — (Pd) ↑↑ (IP) ↓ GTP-bound [34] 
R1398L/D1994A Full Length (M) ↓↓ (Pd) ↓↓ (IP) ? [34] 
R1398L/T1343V/G2019S Full Length (M) — (Pd) — (IP) — [34] 
R1398L/T1343V/D1994A Full Length (M) ↓↓ (Pd) ↓↓ (IP) ? [34] 
R1398Q Full Length (M) — (Pd) — (IP) — [34] 
R1398Q/T1343G 
Roc + COR + kinase 
(Y) 
↓ (Pd) ↑ (IP) ↓ GTP-bound [33] 
R1398Q/T1343G Full Length (M) — (Pd) — (IP) — [34] 
Figure 1 – A schematic model of LRRK2 structure. LRRK2 contains N-terminal 
armadillo (ARM), ankyrin (ANK) and leucine-rich repeats (LRR), with WD40 repeats 
at the C-terminus. The enzymatic core is comprised of Ras-of-complex (Roc) and C-
terminal of Roc (COR) domains (shown in magnified box), and a kinase domain. PD-
causing mutations are shown in red, risk variants in purple, and the protective 
R1398H variant in green.  Motifs conserved with small Ras-like GTPases are shown 
as white boxes and illustrate the guanine nucleotide phosphate-binding motif (P-loop 
- P), switch I (S1), switch II (S2) conformational switch regions, and G4 and G5 loops. 
 
Figure 2 – Possible models of the LRRK2 GTPase. (A) A Ras small GTPase model of 
LRRK2 when GDP-bound (top) and GTP-bound (bottom). The action of suggested 
LRRK2 GEFs and GAPs is depicted. (B) A GAD-based model of LRRK2, obligate COR-
mediated dimeric form (top) shifting to a GTP-dependent cis-dimerisation of the Roc 
domains (bottom).  
 
Figure 3 – Possible LRRK2 pathomechanisms. (A) A substrate that interacts with 
multiple domains of wildtype LRRK2 (black arrows), and undergoing basal levels of 
phosphorylation by the LRRK2 kinase domain (red arrow). (B) Substrate 
phosphorylation is increased directly by the G2019S mutation, or (C) indirectly by 
other PD-causing mutations that enhance enzyme-substrate interaction. (D) 
Alternatively, pathological mutations throughout LRRK2 might affect individual 
protein-protein interactions within a common multiprotein complex. 
 
Table 1 – Summary of data from all publications investigating the effects of RocCOR 
domain mutations on LRRK2 GTPase activity. Expression systems are indicated: M = 
mammalian cells, B = bacteria, Y = yeast, I = insect cells. Up- and down-arrows 
represent statistically significant increases and decreases relative to wild-type 
protein.  Approximate strength of change is represented by number of arrows, where 
one arrow indicates ≤1.5-fold, two arrows between 1.5- and 3-fold, and three arrows 
greater than 3-fold; where numerical values are not reported comparisons are 
estimated. Types of GTP-binding experiment are represented as: Pd = pulldowns of 
LRRK2 protein from cellular lysates with GTP-coupled beads; R = radiolabelled 
nucleotide binding assays using purified protein; F = fluorescently labelled nucleotide 
binding assays using purified protein. The use of purified protein (Pu) or 
immunoprecipitates (IP) in GTP hydrolysis experiments is also shown.  * Indicates 
data referred to in text but not shown. ** Clear but non-significant trend towards 
decreased GTPase activity. Note mutations at T1343 and D1994A are artificial Roc 
domain and kinase-dead mutations. 
  
   
   
 
